NASDAQ:VTVT - vTv Therapeutics Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $1.44 -0.02 (-1.37 %) (As of 07/20/2018 04:00 PM ET)Previous Close$1.46Today's Range$1.42 - $1.5052-Week Range$0.65 - $8.40Volume47,013 shsAverage Volume985,827 shsMarket Capitalization$47.59 millionP/E Ratio-0.87Dividend YieldN/ABeta1.85 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers, develops, and sells orally administered small molecule drug candidates worldwide. The company's drug candidates comprise azeliragon (TTP488), an orally administered, small molecule antagonist targeting the receptor for advanced glycation endproducts, which is in Phase III clinical trials for the treatment of Alzheimer's disease. Its drug candidates also include TTP399, an orally administered, liver-selective glucokinase activator that has completed Phase 2b clinical trials for the treatment of type 2 diabetes, as well as initiated Phase 1b/2 clinical trials for the treatment of type 1 diabetes; and TTP273, an orally administered, non-peptide agonist that targets the glucagon-like peptide-1 receptor, which has completed Phase II clinical trials for the treatment of type 2 diabetes. vTv Therapeutics Inc. has a license and research agreement with Calithera Biosciences, Inc. to develop and commercialize its hexokinase II inhibitors for therapeutic, prophylactic, preventative, or diagnostic use. The company was founded in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of vTv Therapeutics Holdings LLC. Receive VTVT News and Ratings via Email Sign-up to receive the latest news and ratings for VTVT and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:VTVT CUSIPN/A Webwww.vtvtherapeutics.com Phone336-841-0300 Debt Debt-to-Equity Ratio-0.09 Current Ratio0.35 Quick Ratio0.35 Price-To-Earnings Trailing P/E Ratio-0.87 Forward P/E Ratio-1.31 P/E GrowthN/A Sales & Book Value Annual Sales$290,000.00 Price / Sales162.97 Cash FlowN/A Price / CashN/A Book Value($4.60) per share Price / Book-0.31 Profitability EPS (Most Recent Fiscal Year)($1.67) Net Income$-16,140,000.00 Net Margins-639.83% Return on EquityN/A Return on Assets-58.08% Miscellaneous Employees56 Outstanding Shares32,820,000Market Cap$47.59 vTv Therapeutics (NASDAQ:VTVT) Frequently Asked Questions What is vTv Therapeutics' stock symbol? vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT." How were vTv Therapeutics' earnings last quarter? vTv Therapeutics Inc (NASDAQ:VTVT) issued its earnings results on Tuesday, May, 15th. The biotechnology company reported ($0.30) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.26) by $0.04. The biotechnology company earned $2.06 million during the quarter, compared to analyst estimates of $3.14 million. View vTv Therapeutics' Earnings History. When is vTv Therapeutics' next earnings date? vTv Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 1st 2018. View Earnings Estimates for vTv Therapeutics. What price target have analysts set for VTVT? 8 Wall Street analysts have issued 12 month price objectives for vTv Therapeutics' stock. Their forecasts range from $4.00 to $28.00. On average, they anticipate vTv Therapeutics' share price to reach $14.7143 in the next twelve months. This suggests a possible upside of 921.8% from the stock's current price. View Analyst Ratings for vTv Therapeutics. What is the consensus analysts' recommendation for vTv Therapeutics? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." Who are some of vTv Therapeutics' key competitors? Some companies that are related to vTv Therapeutics include ContraFect (CFRX), Tocagen (TOCA), Menlo Therapeutics (MNLO), Neos Therapeutics (NEOS), Syndax Pharmaceuticals (SNDX), VERONA PHARMA P/S (VRNA), VBI Vaccines (VBIV), Nature's Sunshine Products Common Stock (NATR), BioXcel Therapeutics (BTAI), NewLink Genetics (NLNK), Innovate Biopharmaceuticals (INNT), Protagonist Therapeutics (PTGX), Tetraphase Pharmaceuticals (TTPH), Newron Pharmaceuticals (NWPHF) and Spero Therapeutics (SPRO). Who are vTv Therapeutics' key executives? vTv Therapeutics' management team includes the folowing people: Mr. Jeffrey B. Kindler, Exec. Chairman (Age 62)Mr. Stephen L. Holcombe, Pres & CEO (Age 61)Mr. Rudy C. Howard CPA, B.A., CPA, Exec. VP & CFO (Age 60)Dr. Larry Douglas Altstiel, Former Exec. VP & Chief Medical Officer (Age 68)Dr. Carmen Valcarce Ph.D., Chief Scientific Officer & Exec. VP When did vTv Therapeutics IPO? (VTVT) raised $125 million in an initial public offering on Thursday, July 30th 2015. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers. Has vTv Therapeutics been receiving favorable news coverage? News coverage about VTVT stock has been trending somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. vTv Therapeutics earned a coverage optimism score of 0.12 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 47.08 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. Who are vTv Therapeutics' major shareholders? vTv Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include MACANDREWS & FORBES INC. (79.80%). Company insiders that own vTv Therapeutics stock include Paul G Savas and Ronald O Perelman. View Institutional Ownership Trends for vTv Therapeutics. How do I buy shares of vTv Therapeutics? Shares of VTVT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is vTv Therapeutics' stock price today? One share of VTVT stock can currently be purchased for approximately $1.44. How big of a company is vTv Therapeutics? vTv Therapeutics has a market capitalization of $47.59 million and generates $290,000.00 in revenue each year. The biotechnology company earns $-16,140,000.00 in net income (profit) each year or ($1.67) on an earnings per share basis. vTv Therapeutics employs 56 workers across the globe. How can I contact vTv Therapeutics? vTv Therapeutics' mailing address is 4170 MENDENHALL OAKS PARKWAY, HIGH POINT NC, 27265. The biotechnology company can be reached via phone at 336-841-0300 or via email at [email protected] MarketBeat Community Rating for vTv Therapeutics (NASDAQ VTVT)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 182 (Vote Outperform)Underperform Votes: 172 (Vote Underperform)Total Votes: 354MarketBeat's community ratings are surveys of what our community members think about vTv Therapeutics and other stocks. Vote "Outperform" if you believe VTVT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VTVT will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/20/2018 by MarketBeat.com StaffFeatured Article: What is a closed-end mutual fund (CEF)?